Claim and evidence Close ×
A news release of Sumitomo Dainippon Pharma and Exscientia (30 January 2020) announces that a phase I clinical study of DSP-1181, which it says was created using artificial intelligence, has been initiated in Japan. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Date 2020-01-30 · announcement Records dated 2020 → Role Articulation Register (kind of text) Nonfiction Scope of the passage A company announcement of a phase I study start. Scope and limits The record documents what this text states, in its register; it is not evidence that the proposition is true and implies no influence on or from any other text. The companies’ own statement; no clinical-trial registry entry was retrieved. The release’s comparison of its exploratory research phase (under 12 months) with a 4.5-year average is the companies’ figure and is not recorded as a result. The research pack headlined it as earliest located; the cross-family check located an earlier company announcement (2013), which holds the role (maintainer decision of 2026-10-30).
The evidence 02 primary source Supports the claim
Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study ↗ Sumitomo Pharma (then Sumitomo Dainippon Pharma) · 2020-01-30
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “announce that a phase I clinical study of DSP-1181, that was created using Artificial Intelligence (AI), has been initiated in Japan for the treatment of obsessive-compulsive disorder as an initial indication.” Location in source First paragraph
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Sumitomo Pharma (then Sumitomo Dainippon Pharma) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 3a5856fdbe40a67bb2b6ee1be1ac6f8528e80fb6a962d31ce3b9a125cc4c920a). News release page dated Jan. 30, 2020 on Sumitomo Pharma's newsroom, as served on 2026-10-30. Its wording can change; earlier wording is not authenticated. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Sumitomo Pharma (then Sumitomo Dainippon Pharma), “Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study”, 2020-01-30. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (31 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. The companies are the primary source for their own announcement. A cross-family machine check (2026-10-30, item A56) answered the record’s question blind from fresh retrievals and located an earlier text; the record was corrected at admission. No human editorial review. primary source Supports the claim
Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study ↗ Sumitomo Pharma (then Sumitomo Dainippon Pharma) · 2020-01-30
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “Exscientia applying its Centaur ChemistTM Artificial Intelligence (AI) platform for drug discovery.” Location in source Second paragraph
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Sumitomo Pharma (then Sumitomo Dainippon Pharma) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 3a5856fdbe40a67bb2b6ee1be1ac6f8528e80fb6a962d31ce3b9a125cc4c920a). News release page dated Jan. 30, 2020 on Sumitomo Pharma's newsroom, as served on 2026-10-30. Its wording can change; earlier wording is not authenticated. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Sumitomo Pharma (then Sumitomo Dainippon Pharma), “Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study”, 2020-01-30. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (12 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. Names the AI platform the release credits. A cross-family machine check (2026-10-30, item A56) answered the record’s question blind from fresh retrievals and located an earlier text; the record was corrected at admission. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. A passage of the document meets the proposition’s criterion. The record documents what the text states, in its register (fiction and satire are labelled); it is not evidence that the proposition is true and implies no influence on or from another text.
Date. Date printed on the release.
Record ID aib-arg-p3-sumitomo-2020